AngioDynamics, Inc. (NASDAQ:ANGO) Shares Purchased by Royce & Associates LP

Royce & Associates LP grew its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 10.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 986,073 shares of the medical instruments supplier’s stock after purchasing an additional 96,138 shares during the period. Royce & Associates LP owned 2.43% of AngioDynamics worth $7,672,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Systematic Financial Management LP grew its position in shares of AngioDynamics by 8.4% during the 2nd quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier’s stock valued at $12,763,000 after buying an additional 162,972 shares during the last quarter. Millennium Management LLC grew its holdings in shares of AngioDynamics by 41.9% during the second quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock valued at $10,850,000 after purchasing an additional 529,861 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of AngioDynamics by 11.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,012,186 shares of the medical instruments supplier’s stock worth $5,940,000 after purchasing an additional 107,764 shares during the period. Western Standard LLC lifted its holdings in shares of AngioDynamics by 878.5% in the 1st quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier’s stock worth $3,072,000 after purchasing an additional 469,906 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in AngioDynamics by 7.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 425,108 shares of the medical instruments supplier’s stock valued at $3,307,000 after purchasing an additional 28,499 shares during the period. 89.43% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO James C. Clemmer bought 20,000 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were purchased at an average price of $6.03 per share, with a total value of $120,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 681,582 shares in the company, valued at approximately $4,109,939.46. This trade represents a 3.02 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders purchased 22,568 shares of company stock worth $135,847 over the last three months. Corporate insiders own 5.40% of the company’s stock.

AngioDynamics Price Performance

Shares of AngioDynamics stock opened at $6.81 on Monday. AngioDynamics, Inc. has a 1-year low of $5.26 and a 1-year high of $8.25. The company has a market capitalization of $276.69 million, a P/E ratio of -1.12 and a beta of 0.67. The business’s fifty day moving average price is $7.00 and its two-hundred day moving average price is $6.77.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. The business had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The company’s revenue was down 14.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.12) earnings per share. On average, research analysts expect that AngioDynamics, Inc. will post -0.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

ANGO has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of AngioDynamics in a research report on Friday, October 4th. Canaccord Genuity Group dropped their price objective on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, October 4th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.